Slide 1: Investor Presentation Q2 2020/21 Results
INVESTOR PRESENTATION Q2 2020/21 RESULTS 12TH OF MAY 2021
Slide 2: Key Messages
KEY MESSAGES 1 Single-use endoscopy is considered one of the most attractive new markets in MedTech ▪ The regulatory environment continues to evaluate current level of contamination and highlight benefits of single-use endoscopy (e.g. recent FDA communication in urology, additional inpatient reimbur
Slide 3: Single-use endoscopy is one of the most attractive new markets in MedTech
SINGLE-USE ENDOSCOPY IS CONSIDERED ONE OF THE MOST 1 ATTRACTIVE NEW MARKETS IN MEDTECH Drivers creating the single-use endoscopy market Expected single-use market in 2025 Increased focus on contamination and USD ~2.5bn I infection control from medical authorities Rapid technology advancements II str
Slide 4: The case for transition to single-use endoscopy continues to strengthen
THE CASE FOR TRANSITION TO SINGLE-USE 1 ENDOSCOPY CONTINUES TO STRENGTHEN FDA issues letter to healthcare providers warning about infection risk within reusable urological endoscopes on the back of 450 filed reports 35 peer-reviewed GI studies on contamination in the last 15 months and high-profile
Slide 5: Business Update
BUSINESS UPDATE
Slide 6: Core business remains impacted by COVID-19 pandemic
CORE BUSINESS REMAINS IMPACTED BY COVID-19 PANDEMIC 2 Core, quarterly reported revenue (DKKm) Low elective procedure volume impacts 600 Anaesthesia (-4%) and PMD (-7%) leading to total Core growth of -5% in Q2 2020/21 500 400 Prolonged lock-downs in Europe is the main driver behind negative total Eu
Slide 7: Visualization grows double-digits on top of high comparable
VISUALIZATION GROWS DOUBLE-DIGITS ON TOP OF 2 HIGH COMPARABLE Strong Visualization growth across all regions Endoscope units sold increased by 21% in Q2 ▪ Visualization grows 17% on top of high comparable Endoscope units sold (‘000) (69% in Q2 2019/20) ▪ Strong Visualization growth in Europe (25%) d
Slide 8: We are building the most advanced offering in pulmonology
WE ARE BUILDING THE MOST ADVANCED OFFERING IN PULMONOLOGY 2 Commercially available aScope™ 4 Broncho aScope™ 5 Broncho HD • Global market share of +30% of ▪ Launch Q4 2020/21 pulmonary endoscopy market and ▪ Most advanced technology market leading single-use penetrating complex diagnostic bronchosco
Slide 9: Continued rapid penetration for aScope 4 RhinoLaryngo
CONTINUED RAPID PENETRATION FOR aScope™ 4 RHINOLARYNGO 2 MARKET OPPORTUNITY: 11M PROCEDURES Highlights for aScope™ 4 RhinoLaryngo Q2 20/21 Monthly global unit sales since launch in 18/19 ▪ aScope™ 4 RhinoLaryngo (ENT) continues to penetrate ENT segment very rapidly, and unit sales are now above COVI
Slide 10: aScope 4 Cysto launch is showing strong potential
aScope™ 4 CYSTO LAUNCH IS SHOWING STRONG POTENTIAL 2 MARKET OPPORTUNITY: 6M PROCEDURES Monthly global unit sales since launch European launch of aScope™ 4 Cysto First 4 months of unit sales in Europe 3.4x aScope™ 3 Broncho aScope™ 4 Cysto May 19/20 Mar 20/21 1 2 3 4 ▪ aScope™ 4 Cysto is the most rap
Slide 11: aScope Duodeno 1.5 expected in market by Q4 2020/21
aSCOPE™ DUODENO 1.5 EXPECTED IN MARKET 2 BY Q4 2020/21 During 1H 2020/21, we have continued our commercial launch of aScope™ Duodeno. 55 ERCP accounts have ordered our aScope™ Duodeno and 13 of them are within the top 100 ERCP centers in the U.S. We have decided to strengthen the product performance
Slide 12: On target to become the world's most innovative endoscopy player
ON TARGET TO FULFILL OUR ASPIRATION TO BECOME THE WORLD’S 3 MOST INNOVATIVE ENDOSCOPY PLAYER In Germany, we have consolidated our R&D The construction has officially started for infrastructure into a new dedicated center for our new manufacturing plant in Mexico. Fully GI single-use endoscopy operat
Slide 13: Our aspiration is to become the most innovative single-use endoscopy player
OUR ASPIRATION IS TO BECOME THE MOST INNOVATIVE SINGLE-USE 3 ENDOSCOPY PLAYER Product Launch aView™ 2 Advance Commercially available Monitors aBox™ Console 2H, 2020/21 Expected launches in 2020/21 aScope™ 4 Broncho aScope BronchoSampler™ VivaSight™ VivaSight™ 2* Q3, 2020/21 Pulmonology aScope™ 5 Bro
Slide 14: Financial Results and Outlook
FINANCIAL RESULTS AND OUTLOOK
Slide 15: Key financial results for Q2 2020/21
KEY FINANCIAL RESULTS FOR Q2 2020/21 REVENUE ORGANIC GROWTH DKK 1,001m 6% 1H 2020/21: DKK 2,014m 1H 2020/21: 20% ENDOSCOPES GROSS MARGIN 379,000 62.2% 1H 2020/21: 749,000 1H 2020/21: 63.8% EBIT EBIT MARGIN DKK 100m 10.0% 1H 2020/21: DKK 248m 1H 2020/21: 12.3% 15
Slide 16: Organic sales growth by geography
Organic revenue growth % ORGANIC SALES GROWTH BY GEOGRAPHY Global North America Europe Rest of the World +6% +6% +2% +18% organic growth organic growth organic growth organic growth 1,001m 437m 447m 117m DKK revenue DKK revenue DKK revenue DKK revenue 17% -4% -7% 9% 4% 4% 25% -33% -15% 16% 27% 9% Vi
Slide 17: Financial results Q2 2020/21
FINANCIAL RESULTS Q2 2020/21 Revenue / DKKm 6.000 6% organic growth 4.000 in Q2 2020/21 and 20% in the half-year. Visualization 1H growth of 48% (49% 1H LY) 2.000 3.567 2.606 2.820 1.013 1.001 0 FY 17/18 FY 18/19 FY 19/20 Q1 2021 Q2 2021 DKKm Q2 Change Change Q2 62.2% gross margin 19/20 % in value 2
Slide 18: Cash flow, assets and debt H1 2020/21
CASH FLOW, ASSETS AND DEBT H1 2020/21 1H 1H Change DKKm 20/21 19/20 in value DKK -25m Cash flow and ratios free cash flow Equal to -1% (-16%) of Cash flow from operating activities 198 -100 298 1H 2020/21 revenue Cash flow from investing activities before acquisitions -223 -179 -44 Free cash flow be
Slide 19: 2020/21 Financial guidance
2020/21 FINANCIAL GUIDANCE Organic revenue growth 17 - 20% EBIT margin 11 - 12% Endoscope units sold 1.3 - 1.4m 19
Slide 20: Q&A
Q&A Conference call DK: +45 3544 5577 UK: +44 333 300 0804 US: +1 631 913 1422 PIN code: 66323014# Please limit your questions to only 3 at a time and get back into the queue if you have additional questions For questions, please press 01
Slide 21: Investor contact information
Investor contact information Share Information Financial calendar Ambu A/S is listed on the stock exchange in 2021 Copenhagen under the symbol AMBU B 17 August Q3 2020/21 For further company information, please visit: 9 November Q4 2020/21 www.ambu.com 14 December Annual General Meeting 2020/21 Inve